Imidazolo-indazol-verbindungen als jak-hemmer
AT1896348TActive Publication Date: 2026-04-15THERAVANCE BIOPHARMA R&D IP LLC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- AT2022744598T
- Authority / Receiving Office
- AT · AT
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-06-25
- Filing Date
- 2022-06-24
- Publication Date
- 2026-04-15
- Estimated Expiration
- 2042-06-24
Abstract
Provided herein are compounds of formula (I): (I) and pharmaceutically-acceptable salts thereof, where A, W, X, Y and Z are defined in the specification. The compounds of formula (I) and pharmaceutically-acceptable salts thereof are Janus kinase (JAK) inhibitors. Also provided herein are pharmaceutical compositions comprising such compounds; and methods of using such compounds to treat, e.g., inflammatory and fibrotic diseases, including respiratory diseases.
Need to check novelty before this filing date? Find Prior Art